Market Access Impact: Rheumatoid Arthritis (EU5) 2016

Saturday, November 18, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 17, 2017 /PRNewswire/ --

Description Compare 10 major RA therapies. Find out if prescription barriers cost your brand market share

Read the full report: https://www.reportlinker.com/p04833584In the EU5 countries, market barriers affect more than 15% of all rheumatoid arthritis (RA) prescriptions, but they don't affect all brands equally. Our survey of 150 rheumatologists
shows that one brand is winning big. Not only does it see the biggest barrier-related market share gain, it takes share from every other brand we looked at. Find out how your brand compares, and what you can do to fight back, in Market Access Impact: Rheumatoid Arthritis (EU5). The report covers major therapies from AbbVie, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Napp/Mundipharma, Roche, and UCB. Handy graphs and charts show you at a glance which of 7 different barriers cost your brand the most market share, and which ones help you take the most share from competitors. Top Takeaways - Nearly all brands are widely prescribed: 75% or more of the doctors surveyed prescribe eight of the 10 brands covered. Almost all of them prescribe the top brand. - Only four brands gain share: Two of them gain significantly while the other two barely gain at all. - One brand is the across-the-board winner: Not only does it gain the most share overall, it's the only brand to take share from all of the other surveyed brands. - Barriers' effect is uneven: Two of the top three barriers affect a small number of brands far more than the rest. - Eliminating barriers would shake up the middle of the market: The 4th and 5th place brands would switch places, as would the 6th and 7th place brands. - Three brands have perception problems: Less than a quarter of doctors surveyed would not consider prescribing those brands. - Market access is not the problem: Barriers related to market access affect far fewer prescriptions than either of the top two barriers. Insight into 10 Major Rheumatoid Arthritis Drugs - Cimzia (certolizumab pegol; UCB) - Enbrel (etanercept; Pfizer) - Humira (adalimumab; AbbVie) - Inflectra (infliximab; Pfizer) - MabThera (rituximab; Roche) - Orencia (abatacept; Bristol-Myers Squibb) - Remicade (infliximab; Merck Sharp & Dohme) - Remsima (infliximab; Napp/Mundipharma) - RoActemra (tocilizumab; Roche) - Simponi (golimumab; Merck Sharp & Dohme) Exploring Important Market Access Issues Market Access Impact: Rheumatoid Arthritis (EU5) explores key issues affecting RA drug manufacturers. You'll learn: How barriers affect market access: - What brands do doctors prescribe the most? - How many prescriptions do barriers affect? - Which barriers have the biggest impact? How barriers affect your brand: - How many doctors prescribe your brand? How many don't, but would consider it? - Why don't doctors prescribe your brand? What do they prescribe instead? - Which competing brands does your brand take market share from? A Report Based on Expert Knowledge We surveyed 150 rheumatologists—30 from each EU5 country (France, Italy, Germany, Spain, UK)—chosen from the largest community of validated physicians in the world. All respondents have: - Been practicing for 2+ years - Prescribed at least one of the listed products - Seen at least 5 patients with rheumatoid arthritis in total in the last month - We conducted the survey between November 1st and 4th, 2016. Read the full report: https://www.reportlinker.com/p04833584 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/market-access-impact-rheumatoid-arthritis-eu5-2016-300558794.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store